Contact
Please use this form to send email to PR contact of this press release:
Zealand initiates dosing of patients in Phase 2 with its stable glucagon analogue, ZP4207, for hypoglycemia in diabetes
TO:
Please use this form to send email to PR contact of this press release:
Zealand initiates dosing of patients in Phase 2 with its stable glucagon analogue, ZP4207, for hypoglycemia in diabetes
TO: